In this study we report that the therapeutic treatment with MET inhibitors, in addition to the intended direct antitumour activity against MET-driven cancers, provides a bystander effect revoking the IFNγ-induction of PD-L1/PD-L2 through the inhibition of JAK-STAT pathway. Here, SOAT1 is linked to cancer.